Abstracts tagged "Surveys"

Abstract Number: 1980 • ACR Convergence 2020
Understanding the Relationship Between Illness Perceptions and Self-Efficacy Among Latin Americans with SLE Through the Hablemos De Lupus Facebook Page
Erica Crosley¹, Claudia Elera-Fitzcarrald², Leandro Gabriel Ferreyra Garrot³, Yurilis Fuentes-Silva⁴, Soledad Ibañez⁵, Bernardo Pons-Estel⁶, Cristina Reátegui-Sokolova⁷ and Cristina Drenkard⁸, ¹The Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Rheumatology. Hospital Nacional Guillermo Almenara Irigoyen. EsSalud; Universidad Científica del Sur, Lima, Peru, ³Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Universidad de Oriente, Ciudad Bolívar, Venezuela, ⁵Sanatorio Güemes, Buenos Aires, Argentina, ⁶Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina, ⁷Hospital Guillermo Almenara Irigoyen; Universidad San Ignacio de Loyola, Lima, Peru, ⁸Division of Rheumatology, Department of Medicine, Emory School of Medicine, Atlanta, GA
Background/Purpose: SLE disproportionately strikes Latinos, who are also at high risk for poor outcomes. Self-efficacy (SE) to manage chronic disease correlates with outcomes through self-management…
Abstract Number: 0019 • ACR Convergence 2020
Lasting COVID-19 Impacts on US Rheumatology Practices
Lynn Price¹, Gianna Melendez¹ and Phil Pouliot¹, ¹spherix global insights, Exton, PA
Background/Purpose: In late 2019, a novel, highly contagious coronavirus (COVID-19), was discovered in China and quickly spread throughout the world, equating to arguably the largest…
Abstract Number: 0676 • ACR Convergence 2020
Surveying Practicing Rheumatologists Regarding Gout Management and Barriers in Gout Care
Joshua Gavin¹, Yashswee KC², Evan Dombrosky³, Nehal Shah⁴ and Youssef Roman⁴, ¹Virginia Commonwealth University School of Medicine, Richmond, ²Virginia Commonwealth University School of Medicine, Henrico, VA, ³Virginia Commonwealth University School of Medicine, Glen Allen, VA, ⁴Virginia Commonwealth University School of Medicine, Richmond, VA
Background/Purpose: The management of gout is heterogeneous across specialties and clinical settings. Gout has been demonstrated to be one of the most poorly managed conditions…
Abstract Number: 0045 • ACR Convergence 2020
Healthcare Practitioner Confidence Assessing Rashes in Patients of Skin of Color with Lupus
Vijay Kannuthurai¹, Jacob Murray², Lisa Zickuhr³ and Ling Chen², ¹Washington University in St. Louis School of Medicine, Hazlehurst, MS, ²Washington University in St. Louis School of Medicine, St. Louis, MO, ³Washington University/B-JH/SLCH Consortium, St. Louis, MO
Background/Purpose: Medical education can promote bias that disproportionately affects patients of color. Patients of color with lupus are especially vulnerable as they often carry a…
Abstract Number: 0863 • ACR Convergence 2020
Residual Treatment Burden, Desired Improvement, and Prioritized Treatment Goals in Systemic Lupus Erythematosus (SLE): Results from the SLE-UPDATE (Understanding Preferences, Disease Activity and Treatment Expectations) Survey in the United States
Diane Kamen¹, Julie Birt², Monica Hadi³, Nashmel Sargalo³, Ella Brookes³, Paul Swinburn³, Leslie Hanrahan⁴, Karin Tse⁵, Natalia Bello⁶, Kirstin Griffing², Maria Silk², Laure Delbecque⁷ and Anca Askanase⁸, ¹Medical University of South Carolina, Charleston, SC, ²Eli Lilly and Company, Indianapolis, IN, ³Evidera, London, United Kingdom, ⁴Carra Group, Milwaukee, WI, ⁵Lupus Foundation of America, DC, WA, ⁶Eli Lilly and Company, Indianapolis, ⁷Eli Lilly and Company, Brussels, Belgium, ⁸Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Literature describes a fairly high degree of satisfaction with SLE therapies, despite patients reporting high rates of adverse event (1-2). The objectives of this…
Abstract Number: 0061 • ACR Convergence 2020
Rheumatologists’ Attitudes Toward Palliative Care and Medical Assistance in Dying
Alexandra Saltman¹, Caroline McGuinty², Gursimran Chandhoke³, Simon Oczkowski⁴, Heather McDonald-Blumer¹, Ebru Kaya⁵ and Kirsten Wentlandt⁶, ¹University Health Network and Sinai Health System, University of Toronto Faculty of Medicine, Toronto, ON, Canada, ²Ottawa Heart Institute and University of Ottawa, Ottawa, ON, Canada, ³Lakeridge Health, Oshawa, ON, Canada, ⁴Juravinski Hospital and McMaster University, Hamilton, ON, Canada, ⁵University Health Network,, University of Toronto Faculty of Medicine, Toronto, ON, Canada, ⁶University Health Network, University of Toronto Faculty of Medicine, Toronto, ON, Canada
Background/Purpose: Despite major advances in the treatment of systemic rheumatic diseases, a population remains—including those with systemic vasculitis, inflammatory myositis and systemic sclerosis—who suffer from…
Abstract Number: 1136 • ACR Convergence 2020
Survey of Medical Cannabis Use in Lupus and Scleroderma
Wassim Karkache¹ and Catherine Ivory², ¹University of Ottawa, Ottawa, ON, Canada, ²University of Ottawa Faculty of Medicine, Rheumatology, Ottawa, ON, CANADA, Ottawa, ON, Canada
Background/Purpose: Despite the lack of research regarding medical cannabis, marijuana and its by-products have gained popularity over the last decades. A 2019 Statistics Canada report…
Abstract Number: 0158 • ACR Convergence 2020
Relationships Between Disease Patterns in RA and Rheumatology Treatment
Kelly O'Neill¹, Kathryne Marks², John Davis³ and Cynthia Crowson⁴, ¹Rheumatoid Patient Foundation, Orlando, FL, ²Rosalind Franklin University of Medicine and Science, North Chicago, IL, ³Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: We previously showed rheumatoid arthritis (RA) patients report diversity in disease activity (DA) patterns that may be associated with treatment response. Patients who describe…
Abstract Number: 1137 • ACR Convergence 2020
Access to Digital Health in an Urban Rheumatology Population
Bruce Youm¹ and Aruni Jayatilleke², ¹University of the Pacific, Arthur A. Dugoni School of Dentistry, San Jose, CA, ²Section of Rheumatology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA
Background/Purpose: Advances in treatment of rheumatologic diseases have increased emphasis on physician and patient use of health information technologies (HIT). While studies indicate that e-health…
Abstract Number: 0159 • ACR Convergence 2020
Patient-Reported Data Show the Impact of Time to Diagnosis in RA
Kelly O'Neill¹, Kathryne Marks², John Davis³ and Cynthia Crowson⁴, ¹Rheumatoid Patient Foundation, Orlando, FL, ²Rosalind Franklin University of Medicine and Science, North Chicago, IL, ³Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: Time from diagnosis to treatment has been well established to correlate with better outcomes in rheumatoid arthritis (RA). Treatment delays are often associated with…
Abstract Number: 1230 • ACR Convergence 2020
Curcumin: Prevalence and Perceived Efficacy in the Treatment of Rheumatoid and Psoriatic Arthritis
Neha Bhaskar¹, Lilian Otalora Rojas², Tara Jehu¹, Shazia Beg¹ and Neha Bhanusali¹, ¹University of Central Florida College of Medicine, orlando, ²University of Central Florida HCA Healthcare GME, Orlando
Background/Purpose: Ancient Eastern medicine has valued the Curcuma longa (turmeric) plant for its powerful medicinal properties. Curcumin is suggested to possess potent anti-inflammatory, antioxidant, antimicrobial,…
Abstract Number: 0166 • ACR Convergence 2020
Prevalence and Impact of Unacceptable Symptom State Among Patients with Psoriatic Arthritis: Results from the National Psoriasis Foundation’s 2019 Annual Survey
Alexis Ogdie¹, George Gondo², Joseph Merola³, Stacie Bell⁴ and Alice Gottlieb⁵, ¹University of Pennsylvania, Philadelphia, PA, ²National Psoriasis Foundation, Portland, OR, ³Brigham and Women's Hospital, Harvard Medical School, Newton, MA, ⁴National Psoriasis Foundation, Portland, ⁵Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Despite many efficacious therapies for PsA, many patients do not achieve remission. Ongoing disease activity leads to many downstream effects including diminished functional ability,…
Abstract Number: 1461 • ACR Convergence 2020
Implementation, Feasibility and Acceptability of Take Charge, an Email Series to Increase Knowledge of Lupus Self-Management Skills
Karin Tse¹, Mary Crimmings², Mike Donnelly², Reid Dossinger², Lauren Metelski² and Latifa Boyce², ¹Lupus Foundation of America, DC, WA, ²Lupus Foundation of America, WASHINGTON, DC
Background/Purpose: The Lupus Foundation of America developed and launched an educational email series, Take Charge, to provide people with lupus educational information, tools and resources…
Abstract Number: 0436 • ACR Convergence 2020
The Addressing Lupus Pillars for Health Advancement (ALPHA) Project: Establishing Consensus and Prioritization of Global Community Recommendations to Address Major Challenges in Lupus Diagnosis, Care, Treatment and Research
Karin Tse¹, Sanjyot Sangodkar², Kathleen Arntsen³, Sang-Cheol Bae⁴, Lauren Bloch², Ian Bruce⁵, Erin Connolly-Strong⁶, Karen Costenbader⁷, Thomas Dörner⁸, Sydney Evans⁹, Timothy Franson², Kenneth Getz¹⁰, Amy Kao¹¹, Kenneth Kalunian¹², Bradley Dickerson¹³, Susan Manzi¹⁴, Eric Morand¹⁵, Yaritza Peña¹⁰, Sandra Raymond¹⁶, Brad Rovin¹⁷, Laura Schanberg¹⁸, Joan Von Feldt¹⁹, Victoria Werth²⁰, Angel Williams²¹, David Zook² and Leslie Hanrahan¹⁶, ¹Lupus Foundation of America, DC, WA, ²Faegre Drinker Consulting, Washington, DC, ³Lupus and Allied Diseases Association, Inc., Verona, NY, ⁴Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁵Centre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁶Mallinckrodt, Austin, TX, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁸DRFZ and Charité University Hospitals, Berlin, Germany, ⁹Lupus Patient Representative, Riverdale, MD, ¹⁰Tufts Center for the Study of Drug Development, Boston, MA, ¹¹EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ¹²University of California San Diego, La Jolla, CA, ¹³Aurinia Pharmaceuticals, Fort Washington, PA, ¹⁴Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ¹⁵Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ¹⁶Lupus Foundation of America, Washington, DC, ¹⁷The Ohio State University, Columbus, ¹⁸Duke University Medical Center, Durham, NC, ¹⁹GlaxoSmithKline, WILMINGTON, DE, ²⁰University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ²¹Lupus Patient Representative, Richmond, VA
Background/Purpose: The Addressing Lupus Pillars for Health Advancement (ALPHA) Project is a global consensus effort to identify, prioritize and address top barriers in lupus impacting…
Abstract Number: 1568 • ACR Convergence 2020
Impact of the SARS-CoV-2 Pandemic on a Cohort of Patients with Rheumatic Complications of Immune Checkpoint Inhibitors: A Registry Survey Study
Nilasha Ghosh¹, Aidan Tirpack², Caroline Benson³, Gregory Vitone³, Karmela Kim Chan² and Anne Bass¹, ¹Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York
Background/Purpose: It is not known whether cancer patients being treated with immune checkpoint inhibitors (ICI) and/or immunosuppression are more vulnerable to SARS-CoV-2 or more apt…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].